- TRADE NAME: Balversa (Janssen Biotech)
- SYNONYM: Balversa
- CLASS: Fibroblast growth factor receptor inhibitor, Tyrosine kinase inhibitor
- HALF-LIFE: 59 hours
- FDA APPROVAL DATE: 04/12/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
CYP2C9 or CYP3A4 inhibitors, CYP2C9 or CYP3A4 inducers, serum phosphate level-altering agents, CYP3A4 substrates, OCT2 substrates, P-gp substrates - PREGNANCY: Based on the mechanism of action and findings in animal reproduction studies, BALVERSA can cause fetal harm when administered to a pregnant woman. There are no available data on BALVERSA use in pregnant women to inform a drug-associated risk.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 04/07/2026
